Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells 4,222 Shares of Stock

June 4, 2026 by InsiderTrades.com

Key Points

Beta Bionics insider Mark Hopman sold 5,329 shares on June 2 at an average price of $12.61, for proceeds of about $67,199. The filing says the sale was to cover tax withholding tied to vesting equity awards.
The stock has been volatile and remains unprofitable, with shares recently trading at $12.45 versus a 200-day average of $17.31 and a one-year range of $8.80 to $32.71. The company reported a quarterly loss of $0.49 per share, though that beat analyst expectations.
Wall Street sentiment is mixed to cautiously positive, with a consensus rating of “Moderate Buy” and an average target price of $19.70. However, several recent analyst price targets have been cut, and the company is facing multiple legal investigations related to possible securities-law issues and slower patient growth.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Steven Jon Russell sold 4,222 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total value of $53,239.42. Following the completion of the sale, the insider directly owned 173,849 shares of the company's stock, valued at $2,192,235.89. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Trading Down 2.7%

BBNX opened at $12.45 on Thursday. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The stock has a market capitalization of $554.59 million, a price-to-earnings ratio of -8.24 and a beta of 3.40. The business has a 50 day moving average of $10.83 and a 200-day moving average of $17.31.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The company had revenue of $27.63 million during the quarter. Equities analysts predict that Beta Bionics, Inc. will post -2.19 EPS for the current year.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

Positive Sentiment: Beta Bionics said it is now publishing near real-time real-world data on its iLet Bionic Pancreas on a public website, which could support investor confidence in the company’s commercial progress and transparency. Article Title
Neutral Sentiment: Several top executives disclosed stock sales on June 2, including CFO Stephen Feider and insiders Steven Jon Russell, Mark Hopman, and Mike Mensinger. Each sale was relatively small and was stated to be for tax withholding related to vesting equity awards, which makes the transactions less concerning than open-market selling, but the volume may still weigh on sentiment.
Negative Sentiment: Multiple law firms, including Robbins LLP and Johnson Fistel, announced investigations into Beta Bionics and its officers/directors over possible securities-law violations and investor losses. These headlines suggest litigation risk and can spark concerns about disclosure practices and governance. Article Title
Negative Sentiment: A shareholder alert said Robbins LLP is investigating whether Beta Bionics executives and directors violated securities laws and breached fiduciary duties, adding to the legal overhang. Article Title
Negative Sentiment: Johnson Fistel also said it is investigating whether investors suffered losses after Beta Bionics reported slower new patient start growth, highlighting concerns that growth momentum may be decelerating. Article Title

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Leerink Partners reduced their price objective on Beta Bionics from $25.00 to $24.00 and set an "outperform" rating for the company in a research report on Wednesday, April 22nd. Wall Street Zen cut Beta Bionics from a "hold" rating to a "sell" rating in a research report on Sunday, March 29th. Lake Street Capital set a $20.00 price objective on Beta Bionics in a research report on Wednesday, February 18th. Stifel Nicolaus reduced their price objective on Beta Bionics from $22.00 to $20.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Finally, UBS Group raised Beta Bionics to a "strong-buy" rating in a research report on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Beta Bionics presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.70.

Get Our Latest Analysis on BBNX

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Summit Securities Group LLC acquired a new position in shares of Beta Bionics in the fourth quarter valued at $52,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock valued at $61,000 after purchasing an additional 1,818 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company's stock valued at $47,000 after purchasing an additional 1,594 shares in the last quarter. Strs Ohio acquired a new position in shares of Beta Bionics in the first quarter valued at $29,000. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Beta Bionics by 139.1% in the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company's stock valued at $64,000 after purchasing an additional 1,863 shares in the last quarter.

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.